Tapentadol er et nyt stærktvirkende analgetikum med to virkningsmekanismer

Ugeskrift for Laeger

Volumn 173, Issue 25, 2011, Pages 1796-1799

  Staahl, Camilla ^a   Drewes, Asbjørn Mohr ^b   Jensen, Niels Henrik ^c  

^a GRÜNENTHAL GMBH   (Germany)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYLPROPYL)PHENOL; NARCOTIC ANALGESIC AGENT; PHENOL DERIVATIVE; TAPENTADOL;

ARTHRITIS; BACKACHE; CHRONIC DISEASE; DIABETIC NEUROPATHY; HUMAN; NEURALGIA; POSTOPERATIVE PAIN; REVIEW; TREATMENT OUTCOME;

ANALGESICS, OPIOID; ARTHRITIS; BACK PAIN; CHRONIC DISEASE; DIABETIC NEUROPATHIES; HUMANS; NEURALGIA; PAIN, POSTOPERATIVE; PHENOLS; TREATMENT OUTCOME;

EID: 79960223677     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Brennan F, Carr DB, Cousins M. Pain management: a fundamental human right. Anesth Analg 2007;105:205-21.
2. Kalso E, Edwards JE, Moore RA et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112:372-80.
3. Freynhagen R, Baron R, Gockel U et al. PainDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911-20.
4. Gilron I, Bailey JM, Tu D et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:1324-34.
5. Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009;13:219-30.
6. Trescot AM, Datta S, Lee M et al. Opioid pharmacology. Pain Phys 2008;11: 133-53.
7. Radbruch L, Grond S, Lehmann KA. A risk-benefit assessment of tramadol in the management of pain. Drug Saf 1996;15:8-29.
8. Andrews CM, Krantz MJ, Wedam EF et al. Methadone-induced mortality in the treatment of chronic pain: role of QT prolongation. Cardiol J 2009;16:210-7.
9. Tzschentke TM, De Vry J, Terlinden R et al. Tapentadol HCl. Drugs Fut 2006;31: 1053-61.
10. Wade E, Spruill WJ. Tapentadol hydrochloride: a centrally acting oral analgesic. Clin Ther 2009;31:2804-18.
11. Wilder-Smith CH, Hill L, Osler W et al. Effect of tramadol and morphine on pain and gastrointestinal motor function in patients with chronic pancreatitis. Dig Dis Sci 1999;44:1107-16.
12. Terlinden R, Kögel BY, Englberger W et al. In vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol 2010;32:31-8.
13. Lötsch J. Opioid metabolites. J Pain Symptom Manage 2005;29:10-24.
14. Lange B, Kuperwasser B, Okamoto A et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010;27:381-99.
15. Wild JE, Grond S, Kuperwasser B et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 2010;10:416-27.
16. Buynak R, Shapiro DY, Okamoto A et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother 2010;11:1787-804.
17. Schwartz S, Etropolski M, Shapiro DY et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy. Curr Med Res Opin 2011;27:151-62.
18. Bhandari P, Bingham S, Andrews PL. The neuropharmacology of loperamideinduced emesis in the ferret: the role of the area postrema, vagus, opiate and 5-HT3 receptors. Neuropharmacology 1992,31:735-42.
19. Aghajanian GK. Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine. Nature 1978;276:186-8.
20. Hale M, Upmalis D, Okamoto A et al. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis over 90 days: a randomized double-blind study. Curr Med Res Opin 2009;25:1095-104.